Protocol Components
Duration & Cycling: 3 to 6 Months
Weekly
Inject Retatrutide (Start 2mg -> Titrate to Tolerance)
Do not micro-dose. Aim for steady therapeutic levels.
Mon/Wed/Fri
Inject MOTS-c (5mg)
To sensitize muscles to glucose.
Daily
Inject BPC-157 (250mcg)
Vascular protection.
Mechanism of Action
This stack treats metabolic disease not as a permanent state but as a 'software error' in signaling.
1. Retatrutide (The Reboot): A Triple Agonist (GLP-1/GIP/Glucagon) that fundamentally alters how the body processes sugar and fat. It aggressively clears liver fat (the root of insulin resistance) via glucagon agonism.
2. MOTS-c (The Sensitivity): Enhances GLUT4 translocation, allowing muscle cells to soak up glucose from the blood independently of insulin, effectively bypassing resistance.
3. BPC-157 (The Protection): Protects the endothelial lining of blood vessels from high blood sugar damage (glycation) and supports the nervous system against diabetic neuropathy.
Protocol Key: Dr. Bachmeyer warns that Retatrutide must be dosed to 'Steady State' (consistent weekly buildup) rather than micro-dosed, to ensure the liver fat clearing mechanism fully engages.
References
- Retatrutide2023NEJM Phase 2NEJM24.2% weight loss at 48 weeks.
- MOTS-c2025MOTS-c improves mitochondrial bioenergeticsFrontiers in PhysiologyStudy on restoration of ATP production in diabetic tissues.
- MOTS-c2024MOTS-c prevents muscle atrophyiScienceHighlights glucose uptake via GLUT4 and mitochondrial fusion.
- BPC-1572025Emerging Use of BPC-157 in Orthopaedic Sports MedicinePubMed CentralSystematic/narrative review summarizing preclinical musculoskeletal findings and discussing limited human evidence.
- BPC-1572025Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal HealingPubMed CentralNarrative/scoping review focusing on mechanisms, potential applications, and safety concerns in musculoskeletal contexts.
- BPC-1572025Stable Gastric Pentadecapeptide BPC 157 as Therapy After Quadriceps Muscle-to-Bone Detachment to Reattachment in RatsPubMedPreclinical rat study exploring functional recovery after muscle-to-bone injury with BPC-157 therapy.
Used For
HbA1c Reduction
Liver Fat Clearance
Insulin Sensitivity
Neuropathy Protection
Important Notes
Hypoglycemia Risk
MOTS-c + Retatrutide powerfully lower blood sugar. Monitor glucose closely.
Research Use OnlyThis information is for educational and research purposes only. Always consult properly licensed professionals.